Literature DB >> 8608215

A monoclonal antibody recognizing CD43 (leukosialin) initiates apoptosis of human hematopoietic progenitor cells but not stem cells.

V Bazil1, J Brandt, S Chen, M Roeding, K Luens, A Tsukamoto, R Hoffman.   

Abstract

CD43 (the major sialoglycoprotein of leukocytes) is an adhesion molecule broadly expressed on hematopoietic cells. A monoclonal antibody recognizing this molecule induces apoptosis of lineage marker-negative bone marrow hematopoietic progenitor cells (HPCs) that express CD34 at a high density (CD34hiLIN-). However, not all cells within this population undergo apoptosis on stimulation via CD43. Dividing progenitor cells are most highly affected, whereas more primitive quiescent cells survive anti-CD43 monoclonal antibody treatment. These surviving cells (1) are enriched for cobblestone area-forming cells, (2) repopulate fragments for human fetal bone implanted into C.B-17 scid/scid mice, (3) have a potential to differentiate in vivo to myeloid and lymphoid cells, and (4) have a high proliferative potential in long-term stromal cell-free liquid culture. These data indicate that cells with hematopoietic stem cell characteristics are relatively resistant to CD43-mediated apoptosis as compared with HPCs. Thus, CD43 may be specifically involved in the regulation of HPC proliferation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8608215

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

1.  Identification of a role for the sialomucin CD164 in myogenic differentiation by signal sequence trapping in yeast.

Authors:  Y N Lee; J S Kang; R S Krauss
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

2.  Leukosialin (CD43) defines hematopoietic progenitors in human embryonic stem cell differentiation cultures.

Authors:  Maxim A Vodyanik; James A Thomson; Igor I Slukvin
Journal:  Blood       Date:  2006-06-06       Impact factor: 22.113

3.  Reduced CD43 expression on the neutrophils of MDS patients correlates with an activated phenotype of these cells.

Authors:  Despina Kyriakou; Michael G Alexandrakis; Elias S Kyriakou; Dimitra Liapi; Taxiarchis V Kourelis; M Mavromanolakis; Ioannis Vlachonikolis; Polyvios Eliakis
Journal:  Int J Hematol       Date:  2001-06       Impact factor: 2.490

4.  How do megakaryocytic microparticles target and deliver cargo to alter the fate of hematopoietic stem cells?

Authors:  Jinlin Jiang; Chen-Yuan Kao; Eleftherios T Papoutsakis
Journal:  J Control Release       Date:  2016-12-24       Impact factor: 9.776

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.